학술논문
Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection
Document Type
article
Author
Aye Mya Sithu Shein; Dhammika Leshan Wannigama; Cameron Hurst; Peter N. Monk; Mohan Amarasiri; Vishnu Nayak Badavath; Phatthranit Phattharapornjaroen; William Graham Fox Ditcham; Puey Ounjai; Thammakorn Saethang; Naphat Chantaravisoot; Wanwara Thuptimdang; Sirirat Luk-in; Sumanee Nilgate; Ubolrat Rirerm; Chanikan Tanasatitchai; Naris Kueakulpattana; Matchima Laowansiri; Tingting Liao; Rosalyn Kupwiwat; Rojrit Rojanathanes; Natharin Ngamwongsatit; Arsa Thammahong; Hitoshi Ishikawa; Daniel Pletzer; Asada Leelahavanichkul; Naveen Kumar Devanga Ragupathi; Pattama Wapeesittipan; S.M. Ali Hosseini Rad; Talerngsak Kanjanabuch; Robin James Storer; Kazuhiko Miyanaga; Longzhu Cui; Hiroshi Hamamoto; Paul G. Higgins; Anthony Kicic; Tanittha Chatsuwan; Parichart Hongsing; Shuichi Abe
Source
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115793- (2023)
Subject
Language
English
ISSN
0753-3322
Abstract
Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration. Recently, adjuvants like CaEDTA have shown the ability to enhance the effectiveness of combined antimicrobial agents. Here, we tested a phage-adjuvant combination and demonstrated the effectiveness of intranasally inhaled phage (KKP10) + CaEDTA in addition to ceftazidime/avibactam (CZA) for chronic P. aeruginosa lung infections. The results emphasize that intranasal inhalation of phage along with CaEDTA can successfully re-sensitize MDR P. aeruginosa to CZA in a triple combination treatment. This promising approach shows potential as a therapy for chronic respiratory tract infections.